We also investigated whether the expression levels of some of the genes of interest (BCL2, BECN1, CD86, CSF1R and MTOR) varied in function of the DLBCL stage (I, II, II and IV), but we did not find any significant difference (Supplementary Figure S3). The gene discussed is CD86; the disease is diffuse large B-cell lymphoma.